Abstract Number: 0259 • ACR Convergence 2021
JIA Diagnoses and Trends from 2006-2019: Has the U.S. ICD-9-to-ICD-10 Transition Created Coding Artifacts?
Background/Purpose: JIA is the most common rheumatic disease of childhood, but recent data on diagnostic trends in the US are lacking. Furthermore, the impact of…Abstract Number: 1620 • ACR Convergence 2021
Pediatric Onset (< 16 Years) Non-infectious Uveitis: Results from Spanish National Registry
Background/Purpose: Pediatric noninfectious uveitis is a major clinical challenge for Pediatric ophthalmologists and rheumatologists. The burden of disease is considerable and etiological diagnosis elusive in…Abstract Number: 0195 • ACR Convergence 2021
JAK Inhibitors in Refractory Adult and Childhood-Onset Still’s Disease
Background/Purpose: Excessive and inappropriate production of pro-inflammatory cytokines such as interleukin IL-1, IL-6 or IL-18, is a pathogenic cornerstone in adult and childhood onset Still’s…Abstract Number: 0260 • ACR Convergence 2021
Impact on Caregivers of Patients with Juvenile Idiopathic Arthritis: A Hospital-based Study from India
Background/Purpose: Juvenile idiopathic arthritis is a chronic disease that impacts patient's physical and mental health. Caregivers act as a bridge between physicians and patients, by…Abstract Number: 1621 • ACR Convergence 2021
Self-reported Transition Readiness of Adolescent Patients with Rheumatologic Disease: Do the Parents Agree?
Background/Purpose: The transition from pediatric to adult rheumatology care is associated with increased disease activity and morbidity. The parent-child relationship is a significant relationship in…Abstract Number: 0241 • ACR Convergence 2021
Psoriasis Rate Is Increased by the Exposure to TNF Inhibition in Children with JIA
Background/Purpose: Paradoxical psoriasis has been increasingly reported in adults after exposure to tumor necrosis factor inhibitors (TNFi). Systematic studies in the pediatric population are lacking.…Abstract Number: 0261 • ACR Convergence 2021
Methotrexate Withdrawal and Outcomes in Participants with Well-controlled Non-systemic JIA Within the CARRA Registry
Background/Purpose: Methotrexate (MTX) is currently the recommended first-line conventional DMARD for the treatment of JIA with oligo- or polyarthritis. There are limited data on how…Abstract Number: 1622 • ACR Convergence 2021
Mind the Gap: The Experience of Adolescents in a Rheumatology Transition Clinic
Background/Purpose: The transition from pediatric to adult healthcare is a critical time for the wellbeing of patients with chronic illness including rheumatologic disease. Low patient…Abstract Number: 0242 • ACR Convergence 2021
FiRst Line Options for Systemic JIA Treatment (FROST): Results from a Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry Consensus Treatment Plan Observational Study
Background/Purpose: The optimal initial treatment for systemic juvenile idiopathic arthritis (sJIA) is unclear. To further study the initial treatment of sJIA, the Childhood Arthritis and…Abstract Number: 0262 • ACR Convergence 2021
High Degree of Inter-patient Heterogeneity in Synoviocyte Hyperplasia and Immune Cells Infiltration in the Synovium of Juvenile Idiopathic Arthritis Patients
Background/Purpose: Increasing evidence indicates that synovial tissue analysis can deliver pathophysiological insights but also individual clinically-relevant information in adult-onset inflammatory arthritides. Little is known about…Abstract Number: 1626 • ACR Convergence 2021
Use of Total Hip Arthroplasty in Patients Under 21 Years Old: A U.S. Population Analysis
Background/Purpose: Total hip arthroplasty (THA) is a treatment option for young patients with severe hip pathology due to congenital, developmental, rheumatologic, traumatic, and other acquired…Abstract Number: 0243 • ACR Convergence 2021
Effectiveness of Abatacept in Patients with JIA, Classified by Category: Results from the PRCSG/PRINTO JIA Real-World Registry
Background/Purpose: Long-term treatment with abatacept, a selective T-cell co-stimulation modulator, is effective and well tolerated in patients with JIA.1–4 The objective of this analysis was…Abstract Number: 0263 • ACR Convergence 2021
Patterns of Medication Switching in Juvenile Idiopathic Arthritis: A Retrospective Analysis of a National Administrative Claims Database
Background/Purpose: Although the increasing availability of biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) has significantly improved outcomes for patients with Juvenile Idiopathic…Abstract Number: 1631 • ACR Convergence 2021
Predictive Factors for Lack of Response to Treatment in a Long-term Cohort of Patients with Juvenile Idiopathic Arthritis-associated Uveitis
Background/Purpose: Uveitis is the main extraarticular complication of juvenile idiopathic arthritis (JIA) with still a significant impact on JIA morbidity, despite continuous improvement in systemic…Abstract Number: 0245 • ACR Convergence 2021
Long-term Safety and Effectiveness of Abatacept Treatment in Patients with JIA: 5-year Results from the PRCSG/PRINTO JIA Real-World Registry
Background/Purpose: Abatacept (ABA) is well tolerated and effective in patients with JIA.1 The Pediatric Rheumatology Collaborative Study Group (PRCSG)/ Paediatric Rheumatology INternational Trials Organisation (PRINTO)…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 20
- Next Page »